Barclays’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Barclays’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13,638	Closed	-$381K	–	7159
2019 Q3	$381K	Sell	13,638 -32,686	-71%	-$530K	﹤0.01%	4465
2019 Q2	$653K	Buy	46,324 +42,657	+1,163%	+$406K	﹤0.01%	4092
2019 Q1	$33K	Buy	3,667 +3,529	+2,557%	+$28.6K	﹤0.01%	6138
2018 Q4	$1K	Sell	138 -7,796	-98%	-$126K	﹤0.01%	6874
2018 Q3	$167K	Buy	7,934 +2,665	+51%	+$63.5K	﹤0.01%	5155
2018 Q2	$158K	Buy	5,269 +1,816	+53%	+$49.5K	﹤0.01%	4923
2018 Q1	$93K	Buy	3,453 +2,336	+209%	+$69.9K	﹤0.01%	5439
2017 Q4	$32K	Sell	1,117 -12,246	-92%	-$336K	﹤0.01%	6033
2017 Q3	$324K	Buy	+13,363	New	+$317K	﹤0.01%	4006

Barclays's DOVA Position: Q4 2019 in Review

Barclays sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 13,638 shares — an estimated $381K sold.

Barclays first reported a position in DOVA in Q3 2017 and held it in 9 quarters. The position peaked at $653K in Q2 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

Barclays reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Barclays sold 13,638 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $381K.
Barclays first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
Barclays's Dova Pharmaceuticals, Inc. Common Stock position peaked at $653K in Q2 2019.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.